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ABSTRACT 
Bioassay programs are integral in a radiation safety program. They are used as a method of 
determining whether individuals working with radioactive material have been exposed and have 
received a resulting dose. For radionuclides that are not found in nature, determining an exposure 
is straightforward. However, for a naturally occurring radionuclide like uranium, it is not as 
straightforward to determine whether a dose is the result of an occupational exposure. The 
purpose of this project is to address this issue within the University of Nevada, Las Vegas’s 
(UNLV) bioassay program. This project consisted of two compartments that studied the 
effectiveness of a bioassay program in determining the dose for an acute inhalation of uranium. 
The first component of the plan addresses the creation of excretion curves, utilizing MATLAB 
that would allow UNLV to be able to determine at what time an inhalation dose can be attributed 
to. The excretion curves were based on the ICRP 30 lung model, as well as the Annual Limit 
Intake (ALI) values located in the Nuclear Regulatory Commission’s 10CFR20 which is based 
on ICRP 30 (International Commission on Radiological Protection). The excretion curves would 
allow UNLV to be able to conduct in-house investigations of inhalation doses without solely 
depending on outside investigations and sources. The second component of the project focused 
on the creation of a risk based bioassay program to be utilized by UNLV that would take into 
account bioassay frequency that depended on the individual. Determining the risk based bioassay 
program required the use of baseline variance in order to minimize the investigation of false 
positives among those individuals who undergo bioassays for uranium work. The proposed 
program was compared against an evaluation limit of 10 mrem per quarter, an investigational 
limit of 125 mrem per quarter, and the federal/state requirement of 1.25 rem per quarter. It was 
determined that a bioassay program whose bioassay frequency varies  per person, depending on 
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the chemical class of material being worked with, in conjunction with continuous air monitoring 
can sufficiently meet ALARA standards.  
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1.0 INTRODUCTION 
Bioassays are a very necessary and important aspect of any radiological program in order 
to ensure that those individuals who are working with radioactive materials are not being 
exposed to excessive amounts of radiation. Currently at the University of Nevada, Las Vegas 
(UNLV), bioassays are a fixed radiation protection measure for those individuals with access to 
radiation laboratories where significant quantities of unsealed material can be used, referred to as 
“level 3 or level 4 laboratories” in the UNLV Radiation Safety Manual, regardless of the activity 
of the material being used by the individual worker. Initial bioassays are conducted when an 
individual’s project and radionuclide being used for the project is determined so that a baseline 
for the individual can be determined. Under the current bioassay program at UNLV, after the 
initial bioassay individuals receive bioassays on a quarterly basis. This bioassay schedule does 
not take into account the amount of activity being worked with, scope of work, radionuclide, or 
the frequency that the individual does laboratory work involving the radioactive material.  
Urine bioassays are currently conducted on a quarterly basis for thirty-five individuals in 
the Radiochemistry program. Of these thirty-five individuals, twenty individuals are tested for 
potential uranium exposure due to occupational practices. Interpreting the data from these 
individuals’ bioassays requires a different approach than other radionuclides. Radionuclides, 
such as plutonium and technetium, are not found in nature, therefore if they are found in the 
body a safe determination can be made that the exposure is the result from an occupational 
exposure. However, uranium is a naturally occurring nuclide, and therefore it can be found 
present in an individual’s body who has never had an occupational exposure. This makes it more 
difficult when testing workers to determine if the uranium found in a sample can be attributed to 
an occupational exposure or an environmental exposure. It is necessary when conducing 
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bioassays to determine at which point above the natural occurrence of uranium is due to an 
occupational exposure. 
The samples are sent to an outside certified laboratory, currently UNLV uses 
TestAmerica, where it costs $150 to test each isotope. Alpha spectrometry is used to measure the 
sample for uranium isotopes: uranium-238, uranium-235, and uranium-234. It is assumed that 
any intake of uranium-233 is included in the final uranium-234 analysis. This is because the 
isotopes energies are very close and the alpha spectrometer is unable to identify each isotope’s 
energy separately. Most uranium sample results are above the minimum detectable limit (MDL), 
which is 1.5E-2 dpm per sample, but are within the acceptable range of 0.05 – 0.5 microgram per 
day as defined for Reference man in ICRP 23. The results seen are attributed to natural 
environmental exposure and potential occupational exposure.  
However, these bioassays are very expensive for the radiological safety program at 
UNLV to conduct on a quarterly basis. With each bioassay costing $150 for thirty-five people, 
that’s a minimum of $5,250 per quarter and $21,000 per year. This figure does not take into 
account any additional testing that may be required to investigate an abnormal bioassay result or 
hiring consultants to evaluate potential positive results. Further investigating potentially positive 
bioassay results can result in an additional of tens of thousands of dollars per incident. From the 
aforementioned total, the question becomes, “Is it possible to reduce the amount of money spent 
on these bioassays while still applying ALARA standards?”  
1.1 Research Objectives 
It may be possible to reduce the amount of money spent on urine bioassays by developing 
a risk-based bioassay program for UNLV, as well as continuing to employ ALARA (As Low As 
Reasonably Achievable) techniques. This risk based program will account for investigation and 
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action limits to be set that determine the frequency of bioassays necessary to protect those 
individuals working with uranium in UNLV’s laboratories. This program will also evaluate the 
use of additional monitoring techniques, such personal air monitoring, to be used with bioassay 
to ensure workers are not being exposed to doses exceeding the set occupational limits. 
Investigation levels will take into account activity levels, frequency of radioisotope usage, the 
radioisotope being used, chemical form of radioisotope, and how the radioisotope is being used. 
By setting risk-based guidelines it would be possible to more accurately determine the number of 
bioassays necessary per person in a year, thus potentially saving money for the program.  
Uranium will be the radionuclide of interest used in determining the possibility of 
developing a risk-based bioassay program. Uranium will be used as the radionuclide of interest. 
Due to uranium occurring in nature, it can exist in the body naturally. Therefore, it is important 
to determine if the amount of uranium found in a worker’s body is as a result of the individual 
being exposed to an occupational exposure or a part of natural body burden resulting from 
environmental exposure. An additional factor that will be used in structuring the bioassay 
program is focusing only on the potential exposure of uranium via an inhalation pathway. This 
pathway was chosen because in a laboratory setting it is the exposure pathway that is most likely 
to occur, therefore making it the largest concern. The scenario used will be if an individual had 
an acute exposure where they inhaled a determined activity of uranium.  
Frequency of urine analysis as an effective bioassay method can result in uncertainties 
when determining if individuals have been exposed to uranium. The proposed research will focus 
on correlating amounts of uranium in urine to time of inhalation and determining whether urine 
analysis should be done more frequently dependent upon the amount of uranium work and also if 
urine analysis alone is sufficient in determining exposure levels. The ICRP 30 model of the 
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Human Respiratory Tract will be the basis of the first part of the project. This is due to the fact 
that it is the model that the Nuclear Regulatory Commission bases its ALI and DAC information 
on. Once the ICRP 30 version of the Respiratory Tract is modeled and coded in MATLAB’s 
Simulink, it will be benchmarked to ensure the values correlate to previously determined values. 
Once benchmarked, the lung model will then be connected to ICRP 30’s Gastrointestinal Tract 
Model and ICRP 30’s biokinetic model to create excretion cures for future use by UNLV. These 
excretion curves will be created from the urine compartment in the model. These excretion 
curves will determine the amount or uranium found in urine at specified days if the urinary 
excretions were studied for one year. 
The excretion curves based off ICRP 30 are being created because federal and Nevada 
state regulations are based off ICRP 30 data. They have not been changed to reflect updated 
information that has been presented in recent publications in ICRP 66, 100, and 68. These curves 
are also experimental and the data created by them cannot be compared against previously 
existing values to determine their accuracy.  
The second part of the project includes utilizing the excretion curves based off ICRP 66’s 
Human Thoracic Respiratory Model (HTRM) and dose coefficients from ICRP 68 to determine 
what bioassay frequency allows for the investigation and evaluation limits to be met. The 
excretion curves that have been accepted and published by Oak Ridge National Laboratory will 
be used to estimate the amount of uranium that was inhaled at time = 0 based on the 
concentration detected via urine bioassay. These values will then be calculated by a monthly, 
quarterly, semi-annual, and annual basis to determine the dose at each time interval. The doses 
calculated will then be compared to the evaluation and investigation limits to determine potential 
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bioassay frequencies. For those doses that require a bioassay frequency of less than a month, 
additional air monitoring will be considered.  
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2.0 BACKGROUND 
2.1 Uranium 
Uranium is a silvery-white metal that occurs naturally as the isotopes Uranium-234, 
Uranium-235, and Uranium-238. These isotopes of uranium are long living alpha emitters whose 
energies are between 4.15 and 4.8 MeV. Uranium’s uses include nuclear reactor fuel (to generate 
electricity), radioisotope production, propulsion steam, and research [7]. Although heavy water 
reactors are able to operate on natural uranium composition, most nuclear reactor fuel require for 
the enrichment of isotope Uranium-235. Because of its small abundance in nature Table 1 
(0.72%), Uranium-235 must be enriched through a process of gaseous diffusion, centrifugation, 
or laser separation. This enriched isotope then undergoes bombardment of thermal neutrons that 
results in fissioning and a large amount of energy is released. By enriching the amount of 
Uranium-235, its concentration increases which in turn allows for a smaller reactor size and 
quality of fuel.  
Table 1: Isotopic Abundance in natural uranium [7] 
Isotope Natural 
Typical 
Commercial 
Feed 
Enrichment 
Depleted 
Uranium-238 99.28 97.01 99.80 
Uranium-235 0.72 2.96 0.20 
Uranium-234 0.0055 0.03 0.0007 
 
As stated before, enriching uranium allows for the concentration of Uranium-235 to be 
increased to at least 3%. The percentage of enrichment varies for the particular type of fuel being 
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created [7]. It should be noted that during the enrichment process the amount of Uranium-234 
also increases and causes the enriched uranium to have a higher activity. From enriched uranium, 
depleted uranium is created as a byproduct. Depleted uranium, in comparison to enriched 
uranium, has a lower concentration of Uranium-234 and 235, a lower activity, and higher 
density. Depleted uranium can be used as counterweights, target elements in Department of 
Energy Plutonium production reactors, research projects, etc.  
2.2 UNLV Bioassay Program 
The Bioassay Program at the University of Nevada, Las Vegas (UNLV) is a requirement 
of the Radiation Safety Program and is managed by the Risk Management and Safety 
Department at UNLV [15]. The program arose from an incident at UNLV on October 1, 2011 
[14]. A urine bioassay sample was reported to have an activity that was above the detection limit 
for uranium, specifically uranium-238, uranium-235, and uranium-234. Due to uncertainties and 
unknowns related to the cause of the potential significant dose, it was not possible to determine if 
the exposure was because of an occupational exposure. For the individual in question the 
following measures were taken: performance of additional urine bioassays, fecal samples, a chest 
count, thorough review of work history, the hiring of an outside consultant, and suspension from 
all lab work [14]. From the investigation it was determined that due to lab work conducted in a 
glove box the individual may have inhaled a mixture of uranium-238 and uranium-233. The 
activity was performed two times in the time span of six months. At the end of the investigation 
it was concluded, that the inhalation exposures did not cause a significant exposure and the 
“false” positive was a result of environmental causes [14]. The individual was from an area in 
Nevada that had a high natural uranium background and their body naturally had high uranium 
levels.  
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Because of the incident, it was determined that UNLV did not have an adequate bioassay 
program. The state of Nevada required UNLV to implement a bioassay program that required 
additional surveillance of individuals working with radionuclides. This additional surveillance 
included instituting a mandatory quarterly bioassay for workers in the radiochemistry program. 
The additional surveillance was not due to a high potential exposure, but was intended to solve 
the problem of poor record keeping at UNLV. 
UNLV currently employs the Radiation Safety Office (RSO) to ensure that the university 
remains in compliance with the University’s licenses, which are a Broad Scope Type A 
Radioactive Materials License No. 03-13-0305-01gRA and a Service License No. 03-13-0305-02 
[15]. These licenses are granted by the state of Nevada to UNLV allows for the Radiation Safety 
Office to develop, direct, and oversee operation of the university’s radiation safety program. In 
implementing the program, the Radiation Safety Committee and the Radiation Safety Officer are 
committed to maintain that doses to the public and workers are kept at ALARA. This is done by 
being responsible for personnel monitoring and dosimetry services, training, radioactive waste 
management, consultation for laboratory design (including shielding and any matters related to 
radiation science or safety [15]. The Radiation Safety Office maintains the authority to stop any 
operation that includes the use of radioactive material that may affect an individual’s health and 
safety, not in compliance with procedures outlined in the Radiation Safety Manuel, NAC 459, or 
UNLV’s radioactive material license’s requirements.  
 Nevada Administrative Code 459, or NAC 459, provides all regulations related to 
hazardous materials [15].  All policies created and enforced by the Radiation Safety Office are 
based off this state regulation. This is because Nevada is one of thirty-seven agreement states in 
the United States. As an agreement state, Nevada has entered and signed an agreement with the 
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Nuclear Regulatory Commission (NRC) which authorizes the state to regulate uses of radioactive 
materials within the state.  
The policy for the University of Nevada, Las Vegas and the NRC is to maintain radiation 
exposure levels at ALARA, As Low As Reasonably Achievable [15]. Radiation exposure limits 
for UNLV are set at 10% of the annual limit, which is 0.5 rem [15]. This limits means that plans 
and precautions are made to ensure that work done at UNLV should not result in an annual dose 
greater than the determined limit. Setting the limit at 0.5 rem also assists in ensuring that workers 
do not exceed the absolute annual limit that has been determined by federal regulations to 
potentially cause a biological effect. The annual limit is defined to be 5 rem by NAC 459.325 
Table 2. The 10% of the annual limit standard does not include the general public or pregnant 
workers. Policies are set in place to ensure that limits are not exceeded.  
Table 2: Annual Limits for Exposure [15] 
Annual Limits for Occupational Radiation Exposure 
Total Effective Dose Equivalent 5000 mrem (0.05 Sv) 
Any Organ Except Lens of Eye 50000 mrem (0.5 Sv) 
Skin and Extremities 
(Shallow Dose Equivalent) 
50000 mrem (0.50 Sv) 
Lens of Eye 
(Lens Dose Equivalent) 
15000 mrem (0.15 Sv) 
Declared Pregnant Worker 
500 mrem (0.005 Sv) 
duration of pregnancy 
 
The current general principle in UNLV’s internal dosimetry policy is that bioassays are 
required after any incident where internal exposure due to deposited radioisotopes is a possibility 
[15]. These bioassays can include testing blood, urine, fecal samples, or nose swabs. Urine and 
fecal bioassay samples are analyzed by an independent certified laboratory to determine 
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exposure of internal radioactive materials. Once samples are collected, they must be stored in 
laboratory issued containers. Samples must then be preserved, packaged, and shipped per the 
laboratory’s instructions.  
In the event of an emergency, there are specific bioassay procedures that have been 
outlined [15]. Immediate evaluation and decontamination of the individual is required once an 
incident occurs where radioactive material may have been inhaled, ingested, or absorbed. If 
during the personal survey contamination is found on the face, nose, or mouth then face smears 
and nasal swabs must be taken. Documentation of the data must be taken in order to ensure that a 
correct analysis can be made. The documentation should contain the following information: time 
contamination event occurred, date of contamination event, what events led to emergency, initial 
and current survey results, and initial contamination levels, radiation dose, and chemical 
exposure. During urinalysis it is important to collect the required urine volume, record the 
individual’s name, and provide all information when sending urine sample to laboratory for 
analysis. For further documentation it is important that the analysis results, calculated committed 
dose equivalent, and total effective dose equivalent are all in the worker’s exposure file. 
Uranium bioassays are currently conducted on a quarterly basis, where 24 hour urine 
collection is used as the sample volume [15]. Those individuals whose samples’ results are 
higher than 125 mrem undergo further investigations. This investigation includes more bioassay 
samples, total body counts, and determining when the potential exposure occurred.  
2.3 ICRP 30 Respiratory System Model 
When discussing uranium intake, the primary routes of concern are inhalation and 
ingestion. The inhalation route of uranium is described through the Respiratory Tract Model. The 
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Respiratory System Model’s purpose is to address the behavior of materials once they enter the 
body via inhalation. This behavior includes distribution, retention, and excreted from the body.  
The Respiratory System Model was first introduced by the International Commission on 
Radiological Protection (ICRP) in 1979 with Publication 30 [4]. It is a dosimetric model that 
relates how a radioactive aerosol enters the body via inhalation. After inhalation, the dose that 
regions within the respiratory system and other organs and tissues in the body receive vary 
because of how distribution of material occurs in the lung. Distribution and retention estimates of 
material is based off a model proposed in a report by the ICRP Task Group on Lung Dynamics 
created in 1966 [4].  The Respiratory System Model from ICRP 30 accounts for particle size, 
defining three retention class based on chemical form, and elimination routes from the lung.  
In the ICRP 30 model, the respiratory system is divided into three regions: nasal passage 
(NP), trachea and bronchial tree (TB), and the pulmonary parenchyma (P)[4]. The model also 
includes the Lymph Nodes as an elimination pathway, where materials in the Lymph Nodes are 
assumed to either reside indefinitely or be transferred to body fluids depending on the 
compartment the materials are located in. To understand the pattern of distribution of particulates 
in the lung, the model assumes that the aerosols had an activity median aerodynamic diameter 
(AMAD) equal to 1 µm. The fraction of inhaled material that is initially deposited into each 
region is described by the following parameters: DN-P = 0.30, DT-B = 0.08, and DP = 0.25 [4]. It is 
assumed in the model that the dose received in the nasopharyngeal region is negligible because 
for most particle sizes the dose received in the nasopharyngeal region is significantly smaller 
than the doses received by other regions [4]. 
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Figure 1: ICRP Respiratory tract model [4] 
The respiratory system model, shown in Fig. 1, is separated according to the three 
aforementioned regions and the clearance pathways that occur in the respiratory system for each 
of these regions. The clearance pathways include: absorption processes and particle transport 
processes [4]. Compartments A, C, and E on the left-side of the model are involved in the 
absorption process; material in these compartments clear to the body fluids. Compartments in B, 
D, F, and G on the right-side of the model are associated with particle transport processes, such 
as mucociliary transport. These processes allow for materials to translocate to the gastrointestinal 
tract. Within compartments H, I, and J multiple processes occur, though its overall goal is to 
remove dust from the lungs. Material in compartment H transfers to compartments I and J where 
they either continue through compartment I to the body fluids or are retained indefinitely in 
compartment J. In Table 3 Associated with each compartment are clearance half-times (T) and 
fractions (F) of material leaving at specific rates.  
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Radionuclides are categorized according to chemical forms that are determined by the 
radionuclide’s metabolic data [4]. With information on the chemical form, it is possible to 
determine the classification of D, W, and Y. Table 3 provides information regarding the three 
solubility classes: Class D, Class W, and Class Y. Class D (days) materials have a clearance half-
time less than ten days. Class W (weeks) materials clearance half-time lasts between 10-100 
days, whereas Class Y (years) materials clearance time is greater than 100 days. These categories 
relate clearance half-times with solubility class, so that it can be determined how long a material 
will be retained in each region of the lung. 
Table 3: ICRP 30 Solubility Classes [4] 
    CLASS 
  D W Y 
Region Compartment T (day) F T (day) F T (day) F 
N-P A 0.01 0.5 0.01 0.1 0.01 0.01 
  B 0.01 0.5 0.4 0.9 0.4 0.99 
T-B C 0.01 0.95 0.01 0.5 0.01 0.01 
  D 0.2 0.05 0.2 0.5 0.2 0.99 
P E 0.5 0.8 50 0.15 500 0.05 
 F N.A N.A 1 0.4 1 0.4 
 G N.A N.A 50 0.4 500 0.4 
  H 0.5 0.2 50 0.05 500 0.15 
L I 0.5 1 50 1 1000 0.9 
 J N.A. N.A. N.A. N.A. ∞ 0.1 
 
2.4 ICRP 66: Human Respiratory Tract Model 
The Respiratory Tract Model was modified and updated in 1994 to the Human 
Respiratory Tract Model (HRTM) [16]. This publication provided values, biokinetics, transport 
rate constants, and a model to better help understand how radionuclides travel through the 
respiratory system. In Fig. 2 the Human Respiratory Tract Model is divided into compartments 
and paths that detail how deposited radionuclides are cleared from the body once inhaled [16]. In 
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this model particle transport competes with particle dissolution, which affects the rate of 
absorption of particles into blood.  Absorption to blood occurs in most parts of the HRTM except 
for the first part of the extrathoracic compartment (ET1). It is assumed that an activity can be 
absorbed resulting from material located in the alimentary tract that resulted from the coughing 
of material from lungs and consequently swallowed [16]. The total activity level excreted via 
urine is determined by the amount of activity absorbed to the blood from the respiratory and 
alimentary tracts.  
 
Figure 2: ICRP Respiratory Tract Model [16] 
The respiratory system is divided into two compartments, the extrathoracic (ET) and 
thoracic tissues [16]. The extrathoracic region is divided into the anterior nasal passage and the 
posterior nasal passage. The anterior nasal passage accounts for the removal of particles and 
deposits through blowing of the nose. Whereas, the posterior nasal passage includes incidents 
where inhaled radionuclides were swallowed or absorbed into the blood. The posterior nasal 
passage is composed of the nasopharynx, oropharynx, and larynx; the larynx is further separated 
into the bronchi (BB), bronchioles (bb), and alveolar interstitium (AI). From the thoracic 
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compartment particles are transferred to the blood through absorption, the gastrointestinal 
(alimentary) tract through mechanical processes, and through the lymphatic channels for the 
lymph nodes (LN) Fig 3 [16]. 
 
Figure 3: Clearance Routes from Respiratory Tract [16] 
Dissolution is also a phenomenon that needs to be considered when discussing the 
chemical and physical forms of the radionuclide in question for an inhalation dose. The rate of 
dissolution is dependent upon the radionuclide’s physical and chemical form [16]. In the HRTM, 
there are two assumed pathways: dissolved activity can bind to respiratory tract tissues and 
activity dissolved in the respiratory system is absorbed immediately to the bloodstream [16]. 
This absorption is then assumed to occur at the same rate in all regions within the model (with 
the extrathoracic (ET1) compartment being an exception since no absorption occurs). This 
absorption rate decreases with time due to values for the relatively soluble, moderately soluble, 
and relatively insoluble aerosols.  
The solubility classes published in ICRP 30 were updated in ICRP 66 to account for how 
different chemical forms would transfer and be retained in the lung. The solubility classes D, W, 
and Y names were changed to absorption types F, M, and S [16] to describe the correlation 
between solubility, dissolution rate, and absorption level. Type F relates to a relatively soluble 
16 
 
material that would undergo a fast dissolution and high absorption level to the bloodstream. Type 
M is a moderately soluble material with a moderate dissolution rate and an intermediate 
absorption level to the bloodstream. Type S is a material that is relatively insoluble with a slow 
dissolution rate and low absorption level to the blood.  
Each absorption type has dissolution parameters related to them that can be applied to 
each respiratory compartment, except ET1 [16]. These parameters include fr , sr, and ss. fr is the 
fraction of deposited material, and sr, and ss are the dissolution rates (rapid and slow 
respectively). In Table 4, Type F has a fr = 1.0, meaning that there is no slow dissolution rate; 
the remaining two types do have fr < 1.0 which is indicative of those materials experiencing 
some slow dissolution rates [16].  
Table 4: ICRP 66 Absorption Types [16] 
Material fr sr (d-1) ss (d-1) 
Type F 1.0 100 - 
Type M 0.1 100 0.005 
Type S 0.001 100 0.0001 
 
Figure 4 shows how the aforementioned parameter are useful in determining material-
specific dissolution rates. The figure correlates dissolution rate with time and assumes that the 
dissolution rate decreases with time [16]. From the figure it is also assumed that a fraction of 
deposited material (fr) dissolves at a fast rate (sr). The remaining fraction (1- fr ) dissolves at a 
slower rate (ss ). 
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Figure 4: Time dependent absorption within the HRTM [16] 
2.5 CDC Fourth National Report on Human Exposure to Environmental Chemicals 
 The Fourth National Report on Human Exposure to Environmental Chemicals published 
by the Centers for Disease Control and Prevention is an assessment of determining 
environmental chemicals the United States population has been exposed to [11]. The purpose of 
the report is to prevent environmental chemical exposure by establishing reference values that 
can be used to determine whether a group or person has been exposed. This assessment was done 
via the use of biomonitoring. Biomonitoring determines chemical exposure by measuring blood 
or urine for chemicals or metabolites. The amount of a chemical present in the body from 
ingestion, inhalation, and absorption is reflected in blood, serum, and urine levels. Although a 
measurement of an environmental chemical in blood, serum, or urine is indicative of exposure, it 
is not definitive in determining if the exposure can result in disease or other effect [11].  
 The report provides geometric means and percentiles of environmental chemicals for age 
groups, genders, and race/ethnicity based on blood, serum, and urine levels. The geometric mean 
provided a better estimate for data that are distributed with a long tail at the upper end of the 
distribution [11]. It is less influenced by high values than the arithmetic mean. This weighted 
mean was calculated with a 95% confidence interval. Also, to provide additional information 
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about the shape of distribution, the 50th, 75th, 90th, and 95th percentiles were provided. The urine 
concentrations used in the geometric mean and percentiles are measured in µg/L. For uranium, it 
is important to note that the report provides information for urinary uranium and urinary uranium 
(creatinine corrected). For calculations done in the project, the values for urinary uranium were 
used because the creatinine accounts for urine dilution that may result from increased fluid use, 
lean body mass, or renal function.  
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Figure 5: Urinary Uranium Geometric mean and selected percentiles of urine 
concentration (in µg/L) for the U.S. population [11] 
 
2.6 Dosimetry Principles 
 In order to determine the dose to a tissue, the committed dose equivalent (CDE), H50, 
must be calculated (Eq. 1). The equation shows that H50 is the total dose equivalent calculated 
for a specific organ or tissue after an intake of radioactive material [4]. When calculating dose to 
tissues and the body, the assumption is generally made for a time period of 50 years. This 50 
year assumption is based on the average working life-time for an adult. 
H50 (T←S) = 1.6 ∙ 10-10 [ US Σ SEE (T←S)]    Sv (1) 
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 US is the number of transformations that is calculated in the target organ or tissue over 50 
years after intake of radioactive material [4]. SEE (T←S) is the specific effective energy which 
is the energy imparted per gram of target tissue from a source tissue. 1.6 ∙ 10-10 is a constant 
describing the number of joules in 1 MeV, 1.6 ∙ 10-13, and the conversion of g-1 to kg-1, 103 [4]. 
 The specific effective energy (SEE) is a variable that takes into account the contribution 
of each radionuclide emitted. Eq. 2 describes how the SEE value is calculated. 
SEE (T←S) = ∑
𝑌𝐸𝐴𝐹(𝑇←𝑆)𝑄
𝑀
 MeV g -1 per transformation (2) 
Where, Y is the yield of radiation type per transformation of radionuclide, E is the 
average or unique energy of radiation (MeV), and AF (T←S) is the absorbed fraction of energy 
in target organ [4]. The absorbed fraction values can be found in ICRP 23 Appendix I for each 
target and source tissue for photon energy [5]. Q is the quality factor for a radiation type. For 
alpha particles the quality factor is 20, for Beta/Gamma rays/X-rays the quality factor is 1, and 
for Neutron/Protons the quality factor is 10 [4]. M is the defined mass of the target organ in 
grams, g.  
Once the committed dose equivalent is calculated, it is used to calculate the effective 
dose in Eq. 3. The weighting factor, WT, is determined from Table 5.  
H E,50  =  ΣT wT HT (3) 
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Table 5: Weighting Factors Recommended for Stochastic Effects [4] 
Organ/Tissue wT 
Gonads 0.25 
Breast 0.15 
Red Bone Marrow 0.12 
Lung 0.12 
Thyroid 0.03 
Bone Surfaces 0.03 
Remainder 0.30 
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3.0 DEVELOPMENT OF ICRP-30 URINE EXCRETION CURVES 
The methodology used to determine the possibility of developing a risk-based bioassay 
program for uranium usage in laboratories was composed of two main components. The first 
component comprised of developing a MATLAB Simulink model of the ICRP 30 Respiratory 
Tract model that can be used by the UNLV Radiation Safety Officer to create uranium excretion 
curves to investigate bioassay cases in house. Because the State of Nevada uses ICRP 30 as the 
basis for its regulations, it was necessary to utilize ICRP 30 methodology to create a model for 
uranium. In this project, a previously modeled MATLAB version of ICRP 30’s biokinetic model 
and Gastrointestinal Tract model [2] was expanded to include the ICRP 30 lung model.  This 
model also includes an integration model that allows for the concentration of uranium in urine to 
be determined from the biokinetic models.  
3.1 MATLAB and Simulink 
MATLAB is a software that is used by engineers and scientists to create and analyze 
systems [3]. In MATLAB, coding and the usage of built-in functions and graphics can be used 
together to create models meant for experimentation. For this project the student version, 
MATLAB R2015b, was used to create models simulating the respiratory tract.  
 The Simulink suite was purchased as an add-on to the MATLAB R2015b version. 
Simulink is a suite that allows for multidomain simulation by providing a block diagram 
environment and, therefore was thought to be the best method of modeling radionuclide 
transportation [3]. It allows for model-based designs to be simulated and continuous 
testing/verification of systems to occur while generating code automatically. In order to create 
the models for ICRP 30’s Respiratory Tract, blocks were used that were provided by the 
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software in its customizable block library. These blocks allowed for solvers necessary for 
modeling and dynamic system simulation. 
3.2 Model Development in MATLAB Simulink  
 Simulink allows for the distribution and retention of radionuclides to be modeled through 
a set of differential equations in order to determine the resulting dose. Previous research done by 
Hrycushko provided the basis for how compartments could be set up and modeled in Simulink 
[1].The ICRP 30 respiratory tract compartment D model created by Hrycushko was selected as a 
template for developing the entire ICRP 30 respiratory tract model. ICRP 30 was modeled in 
Simulink because it is the basis for NRC Guidelines and it is still used as the basis for regulations 
for UNLV and Federal entities. Compartments of the ICRP 30 Respiratory System were modeled 
to depict the inhalation, distribution, and retention of a radionuclide and then later connected 
with ICRP 30 Gastrointestinal Tract and Biokinetic models to determine resulting activity found 
in urine [2]. 
Eq. 4 is an example of the first order differential that was modeled via Simulink. This 
equation is specific to Compartment A in the ICRP 30 Respiratory System Model [4]. This 
describes how material is cleared from the compartment and how activity is derived in 
Compartment A at time t. Each compartment of the Respiratory System Model has a specific 
differential equation that is similar to Eq. 4 that takes into account how a radionuclide is handled 
specifically for each compartment.  
𝑑
𝑑𝑡 
 qa(t) = I(t) ∙ DN-P ∙ Fa – λaqa(t) – λRqa(t) (4) 
Where: 
 I(t) is the initial amount inhaled 
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D is the fraction of the initial inhaled amount that is deposited in a region of the lung 
F is the defined fraction of material entering a compartment 
λa-i is the biological clearance rate specific to each compartment 
 λR is the radioactive decay constant for the radionuclide in question 
 Eq. 5 was used to calculate the biological clearance rate (λa-I) and Eq. 6 was used to 
calculate the radiological decay constant (λR) [4]. Eq. 5 was provided in ICRP 30 as the method 
of determining the biological clearance rate. For both variables, time was converted from days to 
seconds. This was done because MATLAB Simulink time runs in seconds and the activity unit 
used in calculations in the model was in Bq (decays per second).  
λ =
0.693
86400T
 (5) 
Where: 
𝜆 = Biological Clearance Rate (s-1) 
T = Removal half-time (days) 
 
λ =
 ln2  
T1/2
 (6) 
Where: 
 T1/2 = half-life of the radioisotope (units in seconds for calculations) 
Fig. 6 depicts how intake and distribution is handled in Compartment A of the ICRP 30 
Respiratory System in MATLAB Simulink.  
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Figure 6: Compartment A Simulink Model 
In calculating the dose conversion coefficient and urine content, an acute inhalation of 1 
Bq at time = 0 was used. A step block was used to depict the initial inhalation. For ICRP 30, the 
assumed AMAD particle size is 1µm. The particle size changes later to 5 µm in ICRP 66 with 
the updated Human Respiratory Tract Model.  This initial activity was then divided amongst the 
compartments in the model. The fraction used for each compartment was based on the assigned 
fraction values outlined in Table 3 detailing the ICRP 30 Solubility Classes.  Once activity was 
derived in each compartment through modeling the aforementioned differential equations, a 
variable step ODE solver was used in the Simulink model to integrate the activity for 50 years. 
This solver determined the total number of transformations (Us) in each compartment that was 
consequently used to calculate the dose from a radionuclide to the Respiratory System. Eq. 2 
was modeled to solve for the specific effective energy (SEE) values, which was then used in 
conjunction with the total number of transformations to calculate the committed equivalent dose. 
The effective dose was then determined for the lung compartment by utilizing Eq. 3.  This value 
included the usage of tissue weighting factors provided in ICRP 26. Fig. 7 shows how the 
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MATLAB Simulink model calculated the total number of transformations, specific effective 
energy (SEE) values, and the committed equivalent dose for the lung compartment. The 
Effective Dose equation was completed in Microsoft Excel. 
 
Figure 7: Calculating Committed Equivalent Dose for Compartment A 
3.3 Model Benchmarking 
Benchmarking the model was necessary to ensure that the model was working correctly. 
This benchmarking was done by running the model at time equals 50 years, in order to compare 
US values, SEE values, and committed equivalent dose values to the literature values provided in 
ICRP 30 for the lung [4]. The time 50 years is significant because that it is the pre-determined 
working life acknowledged for an individual and is the defined time interval for committed dose. 
The radionuclide that was chosen to build the initial lung model was Uranium-238 and Class Y 
materials. Class Y materials were used because all solubility class values were available and it 
27 
 
represents the material with the longest clearance time. The literature values for the US, SEE, and 
committed equivalent dose that correspond to Uranium-238 were used as benchmarking values.  
Tables 6 is the comparison between the values output by the Simulink model and the 
ICRP 30 literature values for the Lung compartment for U-238 at time equals 50 years. The 
values created by the Simulink model ranged from 1.37 to 4.44% different from the literature 
value. This difference could be attributed to the fact that the daughters of U-238 were not 
accounted for in the model’s calculations. The radiological half-life for the radionuclide of study 
and chemical class of material can be changed within the model in order to study how lung dose 
for various radionuclides can be calculated. 
Table 6: Benchmarking Comparing Simulink Model Values to ICRP 30 Values 
 
Simulink 
Model 
Literature 
Value 
Percent 
Difference 
Number of Transformations  
(Transformations/Bq) 
1.93E+07 1.90E+07 1.37 
Specific Effective Energy                       
(MeV per g per Transformation) 
8.37E-02 8.50E-02 1.48 
Committed Dose Equivalent (Sv/Bq) 2.58E-04 2.70E-04 4.44 
Effective Dose  (Sv/Bq) 3.096E-05 3.20E-05 3.25 
 
In Table 6, the lung compartment’s contribution to the effective dose was calculated by Eq. 3 
where the weighting factor was defined as 0.12 for the lung. 
3.4 Development of Excretion Curves 
 Once the values were benchmarked and deemed acceptable the lung model was then 
connected to ICRP 30 Gastrointestinal Tract and Biokinetic models that were created in an 
adjacent project [2]. The initial intake continued to be modeled as an acute inhalation of 1 Bq in 
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the lung model. Because the Gastrointestinal Tract model had previously been used to determine 
an ingestion dose, it was necessary to ensure that the initial activity in that particular model was 
set to 0, so that the only activity seen would be due to the initial activity in the lung. Exports 
from the lung model were also connected to the existing Gastrointestinal Tract and Body Fluids 
compartments for a total activity to be calculated for the entire model.  
 
Figure 8: Lung Model Subsystem 
Figure 8 is an example of a subsystem that was used in the MATLAB Simulink model. 
The Lung model compartment shown in the figure is a subsystem [3]. It is a basic representation 
of the information that is inported and exported in the model. Inports can be information such as 
constants or information that is taken from another subsystem. Exports can be information that is 
connected to another subsystem, graphs, or displays that show the numerical value calculated in 
the subsystem [3]. For the subsystem shown in the figure, the exports are a mixture of 
information sent to other subsystems, Body Fluids and GI Tract, and numerical displays of 
information calculated in the subsystem, SEE and Organ Dose. 
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Figure 9: MATLAB Simulink Model Computing Total Urine Activity 
Fig. 9 is a urine compartment was added to the model to calculate the total activity 
derived from the Biokinetic Model. This urine compartment contains a “Simout” block that 
allows for an input signal and writes the signal data created from the model to a MATLAB 
workspace [3]. Once the data, uranium activity in urine per unit time, is exported to the 
MATLAB workspace, it is used in a code that was created to determine the graphical integration 
for any specific time period. For the purpose of the project the specified time periods were 30 
days, 90 days, 180 days, and 360 days. Each graphical integration was ran for an entire 24 hours 
because bioassay sample volumes are collected in 24 hour voids. The model ran for 370 days and 
output the activity value that corresponded to the given time period. The model was run for 370 
days to determine if the amount of uranium in urine changed after the 360 days (annual) 
bioassay. 
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The excretion occurs in two distinct phases, therefore there were two models created to 
simulate and capture this excretion behavior of uranium into urine. The first excretion includes 
the direct impulse of activity that stems from the body fluids released from the lung and the 
Gastrointestinal Tract. The second excretion curve does not include this direct impulse because 
the direct impulse is the dominant action shown in the resulting curve and does not depict how 
activity is excreted via various other pathways. The models were separated so that the 
contribution from each impulse could be observed and examined separately. Fig. 10 depicts the 
behavior of the material when the direct impulse is not included in the excretion curve for Class 
D materials. Fig. 11 depicts when the direct impulse from the Body Fluids is included in the 
excretion curve for Class D materials. The top curve in Fig. 11 was the curve excreted in the 
MATLAB workspace, whereas the bottom curve was a close up of the workspace curve provided 
by a scope added to the subsystem in order to observe a more detailed view of the curve. The 
direct impulse is the prominent action seen because it is greater than the activity amounts that 
undergo the biokinetic model. The excretion curves for Class W and Y materials are located in 
Appendix A. The difference in activity for each of these excretion curves is shown in Tables 7 
and 8.  
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Figure 10: Class D Material Excretion Curve (No Direct Impulse) 
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Figure 11: Class D Material Excretion Curve (Including Direct Impulse) 
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Table 7: Urine Activity (Bq) Values per 24-hr (Not Including Direct Impulse)  
 Class D Class W Class Y 
Time 
(day) 
Activity 
(Bq) 
Activity 
(Bq) 
Activity 
(Bq) 
30 4.18E-07 1.25E-07 5.84E-09 
90 4.34E-08 4.08E-08 2.46E-09 
180 3.14E-09 1.27E-08 2.18E-09 
360 5.32E-10 1.41E-09 2.096 E-9 
 
Table 8: Urine Activity (Bq) Values per 24-hr (Including Direct Impulse) 
 Class D Class W Class Y 
Time 
(day) 
Activity 
(Bq) 
Activity 
(Bq) 
Activity 
(Bq) 
30 4.24E-07 1.48E-07 2.23E-08 
90 4.63E-08 1.096E-07 1.82E-08 
180 3.97E-09 1.17E-07 1.75E-08 
360 6.007E-10 1.147E-07 1.91E-08 
 
The excretion curves displayed showed the activity excreted over one year and were 
created for Uranium-238 for solubility class D, W, and Y. In the lung model, the T and F values 
Table 3 had to be changed for each compartment in the lung model and the f1 Table 9 value was 
changed in the small intestine model to account for solubility class differences. For 
compartments where there was not a T and F value provided, the previous solubility class 
information was used. Solubility Class Y was used for missing values in Class W and Class W 
values was used for missing values in Class D. There was no method of benchmarking the 
created excretion curves because there was not an excretion curve based on ICRP 30 found in 
research. 
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Table 9: f1 values for Inhalation Classes [4] 
Inhalation 
Class 
f1 
D 0.05 
W 0.05 
Y 0.002 
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4.0 BIOASSAY PLAN DEVELOPMENT 
Currently, bioassay results are studied to determine whether they are above the MDL. 
Most samples do come back as being above the MDL, however they are in the range of the 0.05 
µg to 0.5 µg per day for reference man. This method could result in the investigation of a high 
number of false positives. A proposed bioassay plan must be able to see beyond the natural 
expected change from a dose and whether a dose can be assigned without risking a dose to the 
natural variance. To allot for this a proposed bioassay plan must take into account variance. The 
minimum detectable activity provided that can be detected by the testing laboratory was 
converted to mass for each uranium radionuclide in question. Variance was then calculated to 
take into account the dose at which false positives should not be seen. Once the variance was 
calculated and applied to each baseline group and uranium radionuclide, a dose was calculated 
for specific time periods.  
 Once the variance is determined, the proposed bioassay plan will be compared to doses 
to determine if they meet the federal requirement of 1.25 rem per quarter and the UNLV 
requirement of 125 mrem. The plan will also be compared to an optimization goal of 10 mrem. 
Through comparing the plan to the aforementioned dose limits, the plan should address the 
minimizing of investigation false positives, reduce additional investigation costs while meeting 
dose limit requirements. 
4.1 Minimum Detectable Level 
The Minimum Detectable Level (MDL) is the lowest amount of activity that can be 
detected via bioassay by Test America, which is the laboratory that processes UNLV’s 24 hour 
void urine bioassay samples. The MDL value reported by Test America, the independent 
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laboratory that tests the bioassay samples, is 1.5 E-2 dpm or decays per minute (0.0002505 Bq) 
and is determined from alpha spectrometry. For the project, it was important to convert the MDL 
activity to a mass that could be used in conjunction with excretion curves provided by Oak Ridge 
National Laboratory. Mass was calculated from the given activity with Eq. 7. The equation was 
set equal to N, where A is the provided MDL value and λ can be calculated by Eq. 6. N was then 
converted from the number of molecules to mass in the units, µg.   
A = λN (7) 
Where: 
 A = Activity (Bq) 
 λ= Decay Constant 
 N = Number of molecules 
The resulting MDL values for radionuclides uranium-238, uranium-235, and uranium-233 are in 
Table 10.  
Table 10: MDL values in µg for Uranium Radionuclides 
Radionuclide MDL (μg) 
U-238 2.01 E-2 
U-235 3.13 E-3 
U-233 7.03 E-7 
4.2 Determining Initial Dose from MDL  
Once the mass was calculated, it was used to determine the initial inhaled mass to 
calculate a dose at t = 90 days. It was assumed that the initial dose would be provided by an 
acute inhalation dose. After inhalation, the uranium activity in urine decreases with time. If the 
assumption that inhalation occurs immediately after the sampling period begins, the maximum 
amount inhaled can be estimated from the ORNL excretion curves. The excretion curves [9] in 
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the Oak Ridge National Laboratory papers provided values for the amount of uranium excreted 
in urine per 24 hours (μg/24h) for Types F, M, and S. The excretion curves provided by Oak 
Ridge National Laboratory were generated using ICRP 66’s Human Respiratory Tract Model and 
ICRP 69’s biokinetic model for systemic uranium in adults [9]. To determine the initial dose a 
setup like Ex. 1 was used; in this example all variables are provided, except for X which is 
calculated via Eq.8. Once the X value, the initial mass calculated (µg), was determined it was 
converted to N, the number of molecules, and was then used in Eq. 7 to determine the activity. 
The activity in Bq was multiplied by a dose conversion factor to then compute the dose.  
Example 1: Determining Dose 
I1 X 
M1 M2 
 
X = 
I1∗M2
M1
 (8) 
Where: 
 I1 = Initial mass at t = 0 on Oak Ridge National Laboratory excretion curves  
 I1 = 1 µg 
 M1 = Corresponding mass for time in question  
 provided by ORNL excretion curve and table  
M2 = Mass calculated from MDL values (µg) 
X = Calculated initial mass (µg) 
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The dose conversion factor for calculations based off NRC regulations was calculated 
from the Annual Limit Intake (ALI) values in NRC regulation 10CFR20, which are based on 
ICRP 30 [8]. This is because federal regulations and UNLV regulations still utilize these older 
values. These ALI values varied according to the radionuclide being used. To determine the dose 
conversion factors in Sv/Bq, ALI values were converted to Bq and were divided into the annual 
limit, 0.05 mSv. Conversely, doses based off newer regulations were calculated using the dose 
conversion factors from ICRP 68 [6]. These values were in Sv/Bq and did not require any 
manipulation to be used. Once the activity was multiplied by the dose conversion factor, it was 
then converted from Sieverts (Sv) to millirem (mrem) because the UNLV quarterly investigation 
limit is 125 mrem.  
 This process was used for each absorption type (F, M, and S) at days 30, 90, 180, and 360 
for the radioisotopes of concern, uranium-238, uranium-235, and uranium-233. These days were 
chosen because these are the options that correspond with the proposed bioassay schedule: 
monthly (30 days), quarterly (90 days), semiannual (180 days), and annual (360 days). Also, it 
was necessary to calculate the mass and resulting dose for uranium-233 because although it does 
not occur naturally, it is still of major concern when monitoring individuals working with 
uranium. If an individual at UNLV was working with uranium and received an exposure via 
inhalation, there may be U-233 in their body that can be attributed to uranium samples used in 
campus labs. 
 The information that results from the Alpha spectroscopy method employed by 
TestAmerica for testing samples, provides one peak. The method is not able to distinguish 
uranium-233 from uranium-234 and reports both isotopes in the same analysis and peak. Because 
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the peak contains counts from both U-233 and U-234, the information calculated specific to 
uranium-233 can be assumed to include uranium-234.  
When calculating the initial mass, X value from Eq. 8, for absorption types F, M, and S 
with the given MDL mass for uranium-238, the only value that changed from Eq. 8 was the 
uranium amount (M1) provided by the excretion curves and tables because it varied with time; 
For days 30 and 90 there was an explicit value provided in the table, however for days 180 and 
360 a linear interpolation was used to determine the value [9]. For isotopes uranium-233 and 
uranium-235, the initial mass, the half-life, MDL mass (M2), and dose conversion/ALI values 
needed to be changed to reflect the respective isotope.  
4.3 Calculating Dose 
Once MDLs were calculated, it was necessary to determine if the current bioassay 
program could meet the evaluation limit of 10 mrem and the investigation limit of 125 mrem 
[12]. The doses were compared against the evaluation and investigation limits rather than the 
annual limit of 5 rem. The doses were compared to the evaluation and investigation limits 
because they were more in line with UNLV’s radiation safety program annual limit goal is 10% 
of the 5 rem [15]. Comparing the calculated doses to the 10 mrem and 125 mrem allows for a 
more proactive bioassay program, rather than reacting after the annual limit has already been 
reached. Utilizing 10 mrem and 125 mrem as values for comparison, provides the radiation 
safety program the flexibility of adding more precautionary measures to protect the worker. This 
helps to avoid the automatic ejection of a worker from the laboratory because their annual limit 
has been reached. 
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Because uranium exists in nature, it can be assumed that individuals have natural levels 
of uranium pre-existing in their body before working with uranium in a laboratory environment. 
These levels are dependent upon the natural background levels of uranium that the individual has 
been exposed to. In order to account for this natural background level, measurement uncertainty 
and the natural variance of uranium in urine must be calculated to develop a bioassay program 
that minimizes the need to investigate false positives. It is necessary to minimize false positives 
to ensure any exposures not related to occupational procedures are not taken into account when 
determining individuals’ annual occupational dose.        
The concept used to calculate the initial mass resulting to the MDL was used. However, 
to calculate the dose, the MDL mass value (M2) was replaced by the variance for each respective 
group. The dose was then calculated for times 30 days, 90 days, 180 days, and 360 days for 
chemical types F, M, and S. This calculation was repeated for radionuclides U-238, U-235, and 
U-233.  
Example 2: Determining Dose 
I1 X 
M1 M3 
 
X = 
I1∗M3
M1
 (9) 
Where: 
 I1 = Initial mass at t = 0 on Oak Ridge National Laboratory excretion curves  
 I1 = 1 µg 
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 M1 = Corresponding mass for time in question  
 provided by ORNL excretion curve and table  
M3 = Variance estimate 
X = Calculated initial mass (µg) 
4.3.1 Estimating Variance in Bioassay Sampling 
 Variance estimates were based off urine concentration values provided by a Center for 
Disease Control and Prevention (CDC) report on human exposure to environmental chemicals 
[11]. The assumptions made from the document in calculating the variance was a confidence 
interval of 95% and the information was taken from groups surveyed from 2001-2002 due to the 
sample size being the largest during that year. The variance was calculated for the 50th percentile, 
75th percentile, and 95th percentile groups for males and females in order to provide a wide scope 
on how variance and dose were related to an individuals’ baseline. Eq. 10 was the equation used 
to calculate variance for the 50th percentile, 75th percentile, and 95th percentile groups.  
Data provided by the CDC was in the units of µg/L, which had to be converted to the 
same units as the ORNL excretion curves (µg/24 hour void) in order to be used in calculations. 
ICRP 23 provided the values for the volume of urine excreted per day (1400 mL/day for males 
and 1000 mL/day for females) [5]. These ICRP 23 values allowed for the CDC data to be 
converted and also allowed for the differences between males and females to be incorporated in 
the calculations necessary to determine the min and max values in Eq. 10.   
v =
max−min
2
 (10) 
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Where: 
 v = variance (μg/day) 
 max/min = values provided by CDC range of values 
 (dependent on percentile and gender) 
The natural isotopic ratios in the uranium body burden must be taken into account in 
order to find the baselines for each isotope. It is necessary to use the natural isotopic ratios 
because uranium found in the general public is due to natural exposure to uranium. This was 
done by taking the natural abundance percentage of each isotope and multiplying it by the 
calculated variance for radionuclides U-238, U-235, and U-233. Since U-233 does not occur 
naturally, the natural abundance for U-234 was used to find the baseline. It is important to note 
that the information in the CDC report was provided in μg/L, so the values had to be converted to 
μg/day to be consistent with the provided Oak Ridge National Laboratory excretion values 
reported in μg/24 hrs.  
 The variance about the 0.05 μg and 0.5 μg action levels currently used by the UNLV 
program is based on the range provided in ICRP 23 for the loss of uranium in urine for reference 
man per day (0.05 μg – 0.5 μg) [5]. By using 0.05 μg and 0.5 μg, the variance is calculated for 
the best and worst case scenario for individuals’ natural uranium body burden before working. 
0.05 μg is representative of the individual who has the lowest amount of uranium in urine and 0.5 
μg is representative of the maximum amount of uranium in urine. The CDC’s 95th percentile 
values were used in Eq. 11 to calculate the variance for males and females for 0.05 μg and 0.05 
μg. Because data from previous bioassays completed for UNLV were not available, the values 
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from the 95th percentile were used because their range and mean were the closest in value to the 
0.05 μg – 0.5 μg range provided by ICRP 23 values.  
v =
max − min
median
 (11) 
Where: 
 v = Percent variance  
 max/min/median = values provided by CDC range of values 
 (dependent on percentile and gender) 
As in the previous variance calculations it was necessary to convert the values to μg/day, 
while also taking into account the volume of urine for each gender. The variance from Eq. 11 
was multiplied by 0.05 μg and 0.5 μg and then natural abundance percentage for the uranium 
radionuclide in question to determine the final variance for 0.05 μg and 0.5 μg.  
 For uranium-233, the natural abundance for uranium-234 was used in calculating the 
variance. Again, this is due to uranium-233 not occurring naturally, but can enter the body via 
occupational practices from working with U-233 and U-238 mixtures in UNLV laboratories. 
Also, because the reported peak from the alpha spectroscopy done by TestAmerica combines 
both uranium-233 and uranium-234, it is necessary to account for the isotope. Including the 
variance in the dose calculations ensures that the dose calculated will minimize the investigation 
of false positives. Also, the assumption is made that the dose calculated is the minimum dose 
seen that does not have any environmental attributing factors; meaning any dose seen above that 
level would be attributed to an occupational exposure. 
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4.4 Examination of the Current UNLV Bioassay Plan 
 The calculated measurement uncertainty above baseline doses for males and females in 
the 50th percentile, 75th percentile, 95th percentile, 0.05 μg, and 0.5 μg at 90 days for 
radionuclides uranium-238, uranium-235, and uranium-233 were evaluated to determine if the 
current bioassay plan would meet the NRC and state annual limit of 5 rem. The doses (in mrem) 
at 90 days were chosen for the comparison because the current bioassay schedule is based on a 
quarterly schedule. The doses chosen for comparison were those that were calculated using the 
dose conversion factors provided by NRC’s 10 CFR 20 due to the resulting doses being larger 
than those doses calculated from ICRP 68’s conversion factors. This was assumed for a more 
conservative approach when comparing doses to annual limits. Looking at Tables 11 and 12, it 
was determined that for both males and females the 0.5 μg type S category in uranium-238 and 
uranium-233 was not able to meet the 1.25 rem/quarter limit.  
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Table 11: Dose Calculations (in mrem) at t = 90 days for Males 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F 
0.01471 0.03923 0.14712 0.22359 2.23586 
Type M 
0.03678 0.09808 0.36779 0.55896 5.58964 
Type S 
20.52828 54.74207 205.28276 311.97987 3119.7987 
U
-2
3
5
 
Type F 
0.00068 0.00182 0.00681 0.01035 0.10350 
Type M 
0.00170 0.00454 0.01702 0.02588 0.25876 
Type S 
0.95030 2.53414 9.50302 14.44227 144.42274 
U
-2
3
3
 
Type F 
0.02402 0.06406 0.24024 0.36511 3.65107 
Type M 
0.06864 0.18304 0.68640 1.04316 10.43162 
Type S 
33.52189 89.39173 335.21898 509.45135 5094.51351 
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Table 12: Dose Calculations (in mrem) at t = 90 days for Females 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F 
0.01051 0.02102 0.11910 0.29048 2.90479 
Type M 
0.02627 0.05254 0.29774 0.72620 7.26199 
Type S 
14.66305 29.32611 166.18128 405.32020 4053.20 
U
-2
3
5
 
Type F 
0.00049 0.00097 0.00551 0.01345 0.13447 
Type M 
0.00122 0.00243 0.01378 0.03362 0.33617 
Type S 
0.67879 1.35757 7.69292 18.76321 187.63215 
U
-2
3
3
 
Type F 
0.01716 0.03432 0.19448 0.47434 4.74342 
Type M 
0.04903 0.09806 0.55566 1.35526 13.55263 
Type S 
23.94421 47.88843 271.36775 661.87257 6618.72569 
 
4.5 UNLV Current Bioassay Schedule Meeting Investigation Limits  
 In Tables 11 and 12, the doses (mrem) at 90 days for each group were then compared to 
the investigation limit to determine if the current bioassay schedule would be able to meet the 
investigation limit. The investigation limit used was 125 mrem. The 125 mrem was determined 
from dividing 500 mrem by 4 to represent the maximum dose a worker could be exposed to per 
quarter and still meet the 500 mrem annual limit outlined by UNLV [15]. It can be determined 
from Tables 11 and 12 that for both genders, uranium-238 and uranium-233 type S materials for 
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groups 95th percentile, 0.05 μg, and 0.5 μg groups were not able to meet the investigation limit. 
For uranium-235 type S materials, the 0.5 μg group was not able to meet the 125 mrem limit.  
4.6 UNLV Current Bioassay Schedule Meeting Evaluation Limits 
In Tables 11 and 12 the doses (mrem) at 90 days for each group were then compared to 
the evaluation limit to determine if the current bioassay schedule would be able to meet the 
evaluation limit. The evaluation limit used was 10 mrem. The 10 mrem was determined from the 
500 mrem annual dose that was deemed by UNLV to be the target for the bioassay program [15]. 
500 mrem is 10% of the NRC/state annual dose of 5 rem, and 10 mrem is 2% of the target 500 
mrem. The assumption of using 2% of 500 mrem was based on NRC Regulatory Guide 8.9 
where the evaluation level for 5 rem was outlined to be 0.02 times the ALI, where the ALI is 5 
rem [12].  
 Again, the doses used for the comparison were those calculated using dose conversion 
factors that were calculated from the NRC 10 CFR 20 ALI values. The values in Tables 11 and 
12 show for both males and females, most groups and chemical types were able to meet the goal 
of 10 mrem. However, for type S in uranium-238 and uranium-233 in all percentiles/groups the 
10 mrem was not met and for uranium-235 type S groups 0.05 μg and 0.5 μg the 10 mrem goal 
was also not met. Type S material not meeting the goal of 10 mrem was predicted due to type S 
materials being insoluble and resulting in larger doses than types F and M.  
4.7 Optimizing Bioassay Program 
 It was determined which groups were able to meet the evaluation and investigation limits 
could be met on a quarterly bioassay schedule. It was then important to determine if the bioassay 
schedule frequency could be changed to optimize the bioassay program. ALARA requires for all 
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reasonable actions to be taken and the current program may be over testing some groups, while 
under testing others such as those individuals working with Class S materials. This can result in a 
more financial burden related to the bioassay program. Studying how changing the bioassay 
frequency allows for it to be determined if some individuals would be able to undergo less 
frequent bioassays, while allowing those individuals who need bioassays more frequently than 
what it currently being done to be protected also.  
To determine bioassay frequency, doses were previously calculated per 30 days, 90 days, 
180 days, and 360 days for males and females. These doses were then studied to determine the 
latest at which a bioassay could be done while still being able to meet the evaluation and 
investigation limit. Tables 13 - 16 show the frequency necessary for males and females to meet 
the evaluation and investigation limit for radionuclide and absorption type. Males and females 
were split to compare whether gender affected bioassay frequency. For a gender neutral bioassay 
program, the more restrictive results would be used to base the program. 
In Tables 13 and 14, groups that required a bioassay to be scheduled on a less than once 
a month schedule, the specific length/number of days in between each bioassay was determined. 
The process for determining the specific bioassay schedule included calculating the ratio of the 
variance specific to the percentile to the calculated mass equal to the evaluation limit of 10 
mrem. This ratio was calculated for each radionuclide and absorption type. The ratio was then 
looked up on an excretion curve provided by the Oak Ridge National Laboratory paper [9] to see 
what day corresponded to the mass. The asterisk (*) located next to some of the frequencies 
denotes that to meet a specific limit, the bioassay frequency fell on the border between two 
schedules. For these situations, a conservative approach was taken and the more frequent of the 
schedules was chosen. 
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Table 13: Bioassay Frequency to Meet 10 mrem (Males) 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F A A A A 2X/YR 
Type M A A A A Q 
Type S < 1 day < 1 day < 1 day < 1 day < 1 day 
U
-2
3
5
 
Type F A A A A A 
Type M A A A A A 
Type S A A Q M < 1 day 
U
-2
3
3
 
Type F A A A A Q 
Type M A A A A M 
Type S < 1 day < 1 day < 1 day < 1 day < 1 day 
 
 
Table 14: Bioassay Frequency to Meet 10 mrem (Females) 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F A A A A Q 
Type M A A A A Q 
Type S 
M < 1 day < 1 day < 1 day < 1 day 
U
-2
3
5
 
Type F A A A A A 
Type M A A A A A 
Type S 
A A 2X/YR < 1 day* < 1 day 
U
-2
3
3
 
Type F A A A A Q* 
Type M A A A A M* 
Type S < 1 day < 1 day < 1 day < 1 day < 1 day 
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Where for all tables: 
A = Annual Bioassay 
2X/YR = Semi-annual Bioassay 
Q = Quarterly Bioassay 
M = Monthly Bioassay 
The same process was used in Tables 15 and 16 to determine the specific day for those 
bioassay schedules less than a month, except the ratio took into account the mass equal to the 
investigation limit of 125 mrem rather than 10 mrem. 125 mrem was evaluated to study whether 
bioassay frequency for each group and radionuclide was affected if the dose limit was increased. 
In Tables 15 and 16, the highlighted values for males and females depict bioassay frequency 
changes for individuals working with a Type S material regardless of the percentile they 
belonged to, as well as individuals in the 0.5 µg group overall. 
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Table 15: Bioassay Frequency to Meet 125 mrem (Males) 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F A A A A A 
Type M A A A A A 
Type S A A M < 1 day < 1 day 
U
-2
3
5
 
Type F A A A A A 
Type M A A A A A 
Type S A A A A M 
U
-2
3
3
 
Type F A A A A A 
Type M A A A A A 
Type S A 2X/YR < 1 day < 1 day < 1 day 
 
Table 16: Bioassay Frequency to Meet 125 mrem (Females) 
  50th 
Percentile 
75th 
Percentile 
95th 
Percentile 
0.05 μg 0.5 μg 
U
-2
3
8
 
Type F A A A A A 
Type M A A A A A 
Type S A A M < 1 day < 1 day 
U
-2
3
5
 
Type F A A A A A 
Type M A A A A A 
Type S A A A A M 
U
-2
3
3
 
Type F A A A A A 
Type M A A A A A 
Type S A A < 1 day < 1 day < 1 day 
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4.8 Summary of Bioassay Plan Development 
 Based on the plans provided in Tables 13 - 16 that measured the feasibility of the current 
quarterly bioassay schedule meeting the evaluation limit of 10 mrem and the investigation limit 
of 125 mrem, the following plan suggests bioassay frequency that meets most working groups 
that takes into account type of material and air monitoring. The doses used in structuring the plan 
were the investigation limit dose of 125 mrem because they were more flexible and less 
restrictive than the evaluation dose. The doses that were calculated were the minimum dose 
above the baseline that would minimize the likelihood of a false positive reading. This was done 
because it is a more realistic limit for the program to abide by as long as stringent air monitoring 
is done in conjunction with the bioassay. It is important that the minimum dose above baseline 
accounts for false positives because the false positives can result in unnecessary investigations. 
Also, because uranium can be detected in urine at levels below the baseline average, the dose is 
never truly zero even though the dose assigned is equal to zero. However, it is better to have 
false positives rather than false negatives when investigating potential doses related to 
occupational exposures. 
The plan stated below uses air monitoring as a 1st line of defense for determining exposures, 
while using a bioassay to support that exposures may or may not have occurred. Utilizing air 
monitoring more aggressively is a preemptive measure that allows for the radiation protection 
program at UNLV to be able to determine when and if there are exposures of concern that occur 
before the current quarterly bioassay. Air monitoring allows for materials, such as Class Y or 
insoluble materials, that cause higher internal dose when exposed and have long retention times 
to be distinguished and proper precautions can be made to ensure the worker does not exceed 
their annual limit. Frequent air monitoring is also beneficial for individuals who work with Class 
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D or soluble materials, since they have short retention types and may void the body before the 
quarterly bioassay that is currently in place.  It also allows for a more tailored bioassay plan that 
is based on an individuals’ baseline and material being worked with.  
The bioassay plan below is designed to meet the goal of ensuring that exposures can be 
detected below the investigational limit of 125 mrem values. The investigation limit was chosen 
as the basis because it allows for flexibility in monitoring the program, unlike the evaluation 
limit of 10 mrem. Although bioassay frequency standards for males and females were provided 
for all type materials and uranium radionuclides of concern, it was determined that the bioassay 
plan does not have to be gender based because there was not a significant difference in the 
necessary frequency. With U-233, it was noted that a more conservative approach should be 
taken for Type S materials. This precaution should especially be taken for females whose 
baseline fall in the 75th percentile region. For the baselines, previous occupational exposure from 
a different job can be included. Also, all workers are required to participate in the bioassay 
program because it is a method of ensuring their safety; if a worker refuses to participate than 
work will be suspended for said worker.  
1. Conduct continuous air monitoring 
A. Plan A: Continuous Air Monitors in laboratories, especially in those where Type Y 
materials are being worked with.   
B. Plan B: If continuous air monitoring is not available to support the work, continuous 
air monitoring can be substituted. Samples are to be collected and counted within 21 
days. 
2. Individuals working with Type F and Type M material (Males and Females) 
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A. All baselines and uranium radionuclides being used: Initial baseline taken before 
work begins and an annual bioassay 
3. Individuals working with Type S material (Males and Females): 
A. U-238 
 Baseline in 50th and 75th Percentile: Annual Bioassay 
 Baseline in 95th Percentile: Monthly Bioassay 
 Baseline in 0.05 µg – 0.5 µg: Monthly Bioassay must be done in conjunction with 
continuous air monitoring 
B. U-235 
 Individuals’ baseline in 50th and 95th Percentile: Annual Bioassay 
 Individuals’ baseline in 0.05 μg: Annual Bioassay 
 Baseline in 0.5 µg: Same as U-238 
C. U-233 
 Individuals’ baseline in 50th: Semi-annual Bioassay 
 Individuals’ baseline in 95th Percentile: Monthly Bioassay must be done in 
conjunction with continuous air monitoring 
o Because performing daily bioassays are unrealistic, monthly bioassays can 
be done in place of daily bioassays as long as continuous air monitoring is 
done. 
 Baseline in 0.05 µg – 0.5 µg: Same as U-238 
The condensed version of the proposed plan located in Appendix C, bases its goal off the 
radiation exposure control limits outlined by UNLV at 0.5 rem, which is 10% of the annual limit 
of 5 rem. This mean that the proposed plan would like to prevent workers from exceeding 125 
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mrem on a quarterly basis, which is the current bioassay schedule. The proposed plan does meet 
the goal of preventing workers from reaching the investigational limit of 125 mrem. Differences 
from the current plan and the proposed plan include: bioassay frequency and taking into account 
individual baselines. Because some baselines require an annual or semi-annual bioassay 
frequency, some money may be saved in the respect of not conducting unnecessary quarterly 
bioassays. For those individuals with a naturally higher baseline, this plan takes into account the 
frequency necessary dependent upon the type of material being used. By utilizing frequency and 
continuous air monitoring, the plan aims to save money in eliminating unnecessary 
investigations.  
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5.0 CONCLUSION 
5.1 Discussion 
 The suggested bioassay program previously mentioned depends on air sampling and then 
using a bioassay as a method of surveillance. In reading NRC Regulatory guide 8.9 and other 
various university radiation protection programs, it was determined that the proposed bioassay 
program uses air sampling as a 1st line of defense. Then proceeding to utilize bioassay as a means 
of ensuring that air sampling is accurately monitoring and protecting workers. Air monitoring 
also allows for a more proactive program that can determine when a potential dose has occurred, 
rather than a reactive program that has to determine when a dose occurred months after it 
happened.  
 The current UNLV program does not take into consideration a worker’s individual 
baseline when determining bioassay frequency. Therefore, the suggested bioassay program 
proposes that by tailoring a bioassay program to each worker there is the possibility for increased 
safety for the worker. Also by making the program more tailored to the worker, it is possible to 
conserve money. This is because it is not necessary to perform a quarterly bioassay on each 
worker when type of radionuclide and absorption type is taken into consideration. If the 
assumption is made that most workers will work with Type F and Type M materials, those 
workers would only need an annual bioassay. This greatly decreases the cost for bioassays on the 
majority; it also frees money to be spent on more frequent bioassays or other additional 
measurements that would be necessary to protect the small percentage of individuals working 
with Type S materials.  
 The ideal bioassay program would include vigilant use of air sampling and using 
bioassays as investigational purposes. If it is not possible to depend on air sampling as an initial 
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line of defense, then a bioassay program that is a hybrid of air sampling and scheduled bioassays 
can be used as a substitute. The bioassay frequency that was initially suggested could be used to 
determine which workers would require more monitoring. Those working with Type S material 
would require additional air monitoring than what is already being done by the Radiation Safety 
Office.  
5.2 ICRP 30 Excretion Curve vs. Oak Ridge National Laboratory ICRP 66/69 curve 
 Although NRC 10 CFR 20 values are the basis for the current UNLV radiation safety 
program, two cases were done to test which excretion curve will provide better values to base a 
bioassay program. The uranium-238 radionuclide was chosen to base the excretion curve 
because it accounts for 99.28% of uranium material. The Oak Ridge excretion curve is based off 
the inhalation of 1 µg of uranium material. Because the experimental excretion curve based off 
ICRP 30 takes initial activity (Bq) to determine dose, it was necessary to first determine the 
activity equal to 1 µg of material. The resulting activity was used to create a new excretion curve 
and activity at predetermined times. The experimental excretion curve was modeled for 10,000 
days, which was the maximum number of days for the Oak Ridge National Laboratory excretion 
curve. 
The times that were chosen to compare the values of each curve was 30 days and 90 days. 
This comparison was done to determine the accuracy of the ICRP 30 excretion curves, as well as 
to see which curve provided the most conservative approach in determining bioassay frequency. 
The initial inhalation for the ICRP 30 curve was 1 µg because that is what was used as the Oak 
Ridge National Laboratory Excretion curve’s initial inhalation mass. Once the activity was 
determined at the aforementioned times, the activity was converted to mass (µg) for comparison 
to the Oak Ridge National Laboratory excretion curves. Tables 17-19 show the comparison of 
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mass of uranium excreted in a 24 hour void between the ICRP 30 experimental excretion curve 
and the Oak Ridge excretion curve.  
Table 17: Mass of uranium in a 24 hour void (Class D Material) 
Time 
(days) 
Activity 
(Bq) 
ICRP 30 Mass 
(µg) 
Oak Ridge Mass 
(µg) 
30 5.5205E-9 4.43E-7 6.6E-4 
90 5.754E-10 4.624E-8 1.2E-4 
 
Table 18: Mass of uranium in a 24 hour void (Class W Material) 
Time 
(days) 
Activity 
(Bq) 
ICRP 30 Mass  
(µg) 
Oak Ridge Mass 
(µg) 
30 1.8727E-9 1.505E-7 2.6E-4 
90 1.8711E-9 1.503E-7 1.2E-4 
 
Table 19: Mass of uranium in a 24 hour void (Class Y Material) 
Time 
(days) 
Activity 
(Bq) 
ICRP 30 Mass  
(µg) 
Oak Ridge Mass 
(µg) 
30 3.0859E-10 2.48E-8 7.6E-6 
90 2.5808E-10 2.07E-8 4.3E-6 
 
 Based on the values in the table, the Oak Ridge National Laboratory excretion curves 
provide the more realistic, but less conservative estimation for the amount of mass that can be 
excreted. These curves are more realistic because the data to create the excretion curves are more 
updated in taking into account how the body functions and deals with radioactive material. This 
amount can then be converted into a useable dose that can be used to determine an initial 
inhalation dose. The values determined in Tables 17-19 are based on ICRP 66, 69, and 100 
which contain more updated values than those provided in ICRP 30. Since current federal and 
state regulations are based on ICRP 30 values, it is suggested that consideration be taken into 
utilizing these values when assigning a more conservative dose. 
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In addition to utilizing ICRP 30 values for assigning more conservative doses, it is 
important to include individual baselines when determining dose for workers. Baselines for the 
initial uranium concentration is an important aspect of uranium internal dosimetry. Baselines 
allow for radiation safety programs to monitor and study fluctuations in an individual’s exposure. 
It also allows for the radiation safety program to determine what range of uranium found in a 
bioassay is considered to be normal or should be of concern. Although the current bioassay 
program uses the baseline values when they are made available, it is important that the bioassay 
frequency reflects the initial baseline. Including the initial baselines would allow for a more 
tailored approach in protecting workers to help ensure there are less false positives detected 
during bioassays, rather than taking a blanket approach with scheduling bioassay frequency. The 
baselines needed for the bioassay frequency would be determined from the initial bioassay done 
on each worker before they begin working with any material.  
5.3 Future Work 
 This work focused primarily protecting those who perform on uranium work at UNLV. 
For future work, it is important that existing bioassay data be made readily available for use in 
determining bioassay frequencies. The existing bioassay data would be pertinent in establishing 
more realistic variance values specific to UNLV workers for the bioassay samples, rather than 
having to utilize values general data from the CDC paper. Potential future work that can be done 
to further increase protection could be considering fecal sample analysis in addition to current 
bioassay measurements. Although fecal sampling is not the most appealing method of bioassay, 
it can provide more accurate measurements to determine dose from exposures.  
Research can also be expounded by developing an excretion curve based on the ICRP 66 
Human Respiratory Tract Model. This project focused on creating an excretion curve based on 
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ICRP 30. The excretion curve based on ICRP 66’s Human Respiratory Tract Model would also 
include the ICRP 100 Human Alimentary Tract and the updated uranium biokinetic model in 
ICRP 69. These are the models that provide the basis for the Oak Ridge excretion curves. It 
would allow for a method of verifying that the excretion curve was created accurately, which 
was not possible for the ICRP 30 model. It would also provide UNLV with the ability to create 
their own updated excretion curves that can vary depending on the amount of inhaled activity.  
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APPENDIX A: Excretion Curves Created in MATLAB 
 
Figure 12: Class W Material Excretion Curve (No Direct Impulse) 
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Figure 13: Class W Material Excretion Curve (Including Direct Impulse) 
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Figure 14: Class Y Material Excretion Curve (No Direct Impulse) 
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Figure 14: Class Y Material Excretion Curve (Including Direct Impulse) 
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APPENDIX B: Dose Calculations  
Table 20: Dose Calculations (in mrem) at t = 30 days for Males 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F 
2.67E-3 7.13E-3 2.67E-2 4.07E-2 4.07E-1 
Type M 
1.70E-2 4.53E-2 1.70E-1 2.58E-1 2.58 
Type S 
1.16E+1 3.10E+1 1.16E+2 1.77E+2 1.77E+3 
U
-2
3
5
 
Type F 
1.24E-4 3.30E-4 1.24E-3 1.88E-3 1.88E-2 
Type M 
7.86E-4 2.10E-3 7.86E-3 1.19E-2 1.19E-1 
Type S 
5.38E-1 1.43 5.38 8.17 8.17E+1 
U
-2
3
3
 
Type F 
4.37E-3 1.16E-2 4.37E-2 6.64E-2 6.64E-1 
Type M 
3.17E-2 8.45E-2 3.17E-1 4.81E-1 4.81 
Type S 
1.9E+1 5.06E+1 1.9E+2 2.88E+2 2.88E+3 
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Table 21: Dose Calculations (in mrem) at t = 30 days for Females 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F 
1.91E-3 3.28E-3 3.17E-2 5.28E-2 5.28E-1 
Type M 
1.21E-2 2.43E-2 1.37E-1 3.35E-1 3.35 
Type S 
8.30 1.66E+1 9.40E+1 2.29E+2 2.29E+3 
U
-2
3
5
 
Type F 
8.84E-5 1.77E-4 1.00E-3 2.44E-3 2.44E-2 
Type M 
5.61E-4 1.12E-3 6.36E-3 1.55E-2 1.55E-1 
Type S 
3.84E-1 7.68E-1 4.35 1.06E+1 1.06E+2 
U
-2
3
3
 
Type F 
3.12E-3 6.24E-3 3.54E-2 8.62E-2 8.62E-1 
Type M 
2.26E-2 4.53E-2 2.56E-1 6.26E-1 6.26 
Type S 
1.35E+1 2.71E+1 1.54E+2 3.74E+2 3.74E+3 
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Table 22: Dose Calculations (in mrem) at t = 180 days for Males 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F 
5.38E-2 1.44E-1 5.38E-1 8.18E-1 8.18 
Type M 
6.71E-2 1.79E-1 6.71E-1 1.02 1.02E+1 
Type S 
2.66E+1 7.09E+1 2.66E+2 4.04E+2 4.04E+3 
U
-2
3
5
 
Type F 
2.49E-3 6.64E-3 2.49E-2 3.79E-2 3.79E-1 
Type M 
3.11E-3 8.28E-3 3.11E-2 4.72E-2 4.72E-1 
Type S 
1.23 3.28 1.23E+1 1.87E+1 1.87E+2 
U
-2
3
3
 
Type F 
8.79E-2 2.34E-1 8.79E-1 1.34 1.34E+1 
Type M 
1.25E-1 3.34E-1 1.25 1.9 1.9E+1 
Type S 
4.34E+1 1.16E+2 4.34E+2 6.6E+2 6.6E+3 
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Table 23: Dose Calculations (in mrem) at t = 180 days for Females 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F 
3.84E-2 7.69E-2 4.36E-1 1.06 1.06E+1 
Type M 
4.79E-2 9.58E-2 5.43E-1 1.32 1.32E+1 
Type S 
1.9E+1 3.8E+1 2.15E+2 5.25E+2 5.25E+3 
U
-2
3
5
 
Type F 
1.78E-3 3.56E-3 2.02E-2 4.92E-2 4.92E-1 
Type M 
2.22E-3 4.44E-3 2.51E-2 6.13E-2 6.13E-1 
Type S 
8.79E-1 1.76 9.96 2.43E+1 2.43E+2 
U
-2
3
3
 
Type F 
6.28E-2 1.26E-1 7.12E-1 1.74 1.74E+1 
Type M 
8.94E-2 1.79E-1 1.01 2.47 2.47E+1 
Type S 
3.10E+1 6.2E+1 3.51E+2 8.57E+2 8.57E+3 
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Table 24: Dose Calculations (in mrem) at t = 360 days for Males 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F 
2.81E-1 7.49E-1 2.81 4.27 4.27E+1 
Type M 
1.87E-1 4.99E-1 1.87 2.84 2.84E+1 
Type S 
3.29E+1 8.78E+1 3.29E+2 5.01E+2 5.01E+3 
U
-2
3
5
 
Type F 
1.3E-2 3.47E-2 1.30E-1 1.98E-1 1.98 
Type M 
8.66E-3 2.31E-2 8.66E-2 1.32E-1 1.32 
Type S 
1.52 4.07 1.25E+1 2.32E+1 2.32E+2 
U
-2
3
3
 
Type F 
4.59E-1 1.22 4.59 6.98 6.98E+1 
Type M 
3.49E-1 9.31E-1 3.49 5.30 5.30E+1 
Type S 
5.38E+1 1.43E+2 5.38E+2 8.17E+2 8.17E+3 
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Table 25: Dose Calculations (in mrem) at t = 360 days for Females 
  
50th 
Percentile 
75th 
Percentile 
95th 
Percentile 0.05 μg 0.5 μg 
U
-2
3
8
 
Type F 
2.01E-1 4.02E-1 2.28 5.55 5.55E+1 
Type M 
1.34E-1 2.67E-1 1.51 3.69 3.69E+1 
Type S 
2.35E+1 4.71E+1 2.67E+2 6.5E+2 6.5E+3 
U
-2
3
5
 
Type F 
9.29E-3 1.86E-2 1.05E-1 2.57E-1 2.57 
Type M 
6.18E-3 1.24E-2 7.01E-2 1.71E-1 1.71 
Type S 
1.09 2.18 1.23E+1 3.01E+1 3.01E+2 
U
-2
3
3
 
Type F 
3.28E-1 6.56E-1 3.72 9.06 9.06E+1 
Type M 
2.49E-1 4.99E-1 2.83 6.89 6.89E+1 
Type S 
3.84E+1 7.68E+1 4.35E+2 1.06E+3 1.06E+4 
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APPENDIX C: UNLV Proposed Bioassay Plan 
TYPE OF 
MATERIAL 
ACTION 
F 
Initial Baseline 
Annual Bioassay M 
S U-238 
Baseline in 50th-75th Percentile: Annual Bioassay 
Baseline in 95th Percentile: Monthly Bioassay 
Baseline in 0.05 µg – 0.5 µg: Monthly Bioassay with CAM 
U-235 
Baseline in 50th-95th Percentile: Annual Bioassay 
Baseline in 0.05 µg: Annual Bioassay 
Baseline in 0.5 µg: Monthly Bioassay with CAM 
U-233 
Baseline in 50th Percentile: Annual Bioassay 
Baseline in 75th Percentile: Semiannual Bioassay 
Baseline in 95th Percentile: Monthly Bioassay with CAM (instead 
of Daily) 
Baseline in 0.05 µg – 0.5 µg: Monthly Bioassay with CAM 
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